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Mitochondria and Alzheimer’s 
Disease: An Electron Microscopy 
Study
Stavros J. Baloyannis
Abstract
Alzheimer’s disease is a progressive, irreversible presenile or senile neurode-
generative disorder, implicating mainly the mental faculties, characterized by 
decline of memory and judgment, learning impairment, loss of professional skills 
and verbal capacities, alterations of social behavior, decline of motor skills and 
eventual disarrangement of the autonomic equilibrium. Among the pathogenetic 
factors, oxidative stress and mitochondrial dysfunction may play an essential role. 
Alterations of mitochondria may enhance amyloid toxicity, which in turn may 
aggravate mitochondrial dysfunction. We describe ultrastructural alterations of 
mitochondria in the soma of neurons, in axons, dendritic profiles and synaptic 
terminals, in astrocytes in early cases of Alzheimer’s disease on various areas of 
the cerebral and the cerebellar cortex, the hippocampus, the hypothalamus, the 
mammillary bodies and the medial geniculate body. The morphological and mor-
phometric study of the mitochondria revealed an impressive polymorphism at any 
area of the brain. The mitochondria demonstrated variation of size and shape, frag-
mentation of the cristae and marked changes of their structure. The most dramatic 
mitochondrial alterations were observed in dendritic profiles, spines and synaptic 
terminals. A substantial number of astrocytes demonstrated mitochondrial altera-
tions, which coexisted with fragmentation of Golgi apparatus and dilatation of the 
cisternae of the smooth endoplasmic reticulum. On the basis of our observations, 
we feel that therapeutic strategies aiming at protecting the mitochondria might be 
beneficial in the treatment of early cases of AD.
Keywords: Alzheimer’s disease, mitochondria, Golgi apparatus, astrocytes, synapses, 
electron microscopy
1. Introduction
Alzheimer’s disease (AD) is one of the most enigmatic and multidimensional 
neurodegenerative diseases of the brain. The high incidence in aging, the ongoing 
number of the patients and the social, humanitarian and economic impact of the 
disease [1], as well as the irreversible course of the disease, the failure of therapeutic 
interventions [2] and the fatal outcome impose on the neuroscientists and the 
society a combined attempt for the amelioration of the quality of life of the patients 
at least by the reduction of risk factors in the initial stages of the disease [3].
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The clinical manifestation of Alzheimer’s disease, starting from the inabil-
ity to encode new memories, includes progressive and irreversible cognitive 
decline, affecting memory and judgment, loss of professional skills and verbal 
capacities, impairment of learning new informations and gradual disarrange-
ment of the social behavior [4, 5] resulting in isolation of the patient in the 
framework of an obvious functional incapacity, encountering in vegetative state 
eventually.
The neuropathological background of AD mostly consists of selective neuronal 
loss [6, 7], substantial morphological and morphometric alterations of the synapses 
[8–11], marked mitochondrial alterations, even in the initial stages of the disease 
[12, 13], tau pathology [14] resulting in the formation of neurofibrillary tangles 
(NFT) by the accumulation of hyperphosphorylated tau protein [15], many inflam-
matory phenomena, alterations of brain capillaries [16] and various extensive 
extracellular deposits of Aβ peptide’s polymers, in the form of polymorphic neuritic 
plaques, [17, 18].
Pathological alterations of the organelles in the soma, the axons, the dendrites 
and the synapses of neurons are observed in electron microscopy, even in the 
initial stage of the disease [19] in areas with minimal typical Alzheimer’s pathol-
ogy, namely aggregations of Aβ peptide and neurofibrillary tangles. The majority 
of the alterations of the organelles in Alzheimer’s disease particularly concern 
the Golgi complex [19], the microtubules, the synaptic vesicles and mostly the 
mitochondria [20–22].
The etiopathology of the sporadic cases of Alzheimer’s disease remains a real 
problem in spite of the multidimensional extensive ongoing research in the last 
decades [23, 24] on the crucial fields of genetics [25, 26], molecular biology [27, 
28], neuropathology [29, 30], neuroimmunology [31, 32], pathophysiology [33], 
neuroimaging [34] and neurochemistry [35–38].
The pathogenetic mechanisms embrace a diverse range of hypotheses which 
attempt to decipher the real cause of memory and reasoning decline in AD. Among 
the many hypothesis, the most mattering are (a) the amyloid hypothesis [39, 40], 
(b) the metabolic and synaptic dysfunction hypothesis [41], (c) the hypothesis 
of translational neurodegeneration [42], (d) the tau hypothesis [43], (e) the 
hypothesis of neuroinflammation [44], (f) the cholinergic hypothesis [45], (g) the 
oxidative stress [46], (h) the vascular hypothesis [47, 48], (i) the glucose hypome-
tabolism hypothesis [49], (j) the autoimmune hypothesis [50], (k) the endocrine 
hypothesis [51, 52], (l) the mitochondrial dysfunction [53, 54] and (m) the Golgi 
complex hypothesis [55–57].
Many of those hypotheses are basely interrelated, such as the amyloid 
hypothesis and the oxidative stress ones [58, 59], the amyloid and the tau 
hypothesis [60], the oxidative stress and the mitochondrial dysfunction [61], 
the mitochondrial dysfunction, energy deficiency and oxidative stress [61, 62], 
the mitochondria dysfunction and the synaptic pathology [22, 63], the tau 
pathology and the vascular hypothesis [64], the cholinergic dysfunction and 
the amyloid hypothesis [65], amyloid, tau and neurodegeneration hypothesis 
[66], the mitochondria and the dendritic hypothesis [67–69] and the immune 
reactions, microglia, tau, Aβ peptide, lipid processing and neurodegeneration 
hypothesis [70–73].
Mitochondria hypothesis advocates in favor of the important role that mitochon-
drial dysfunction may play in the early stages of Alzheimer’s disease [21] by induc-
ing energy deficiency and oxidative stress [22], which would be associated with 
β-amyloid (Aβ) neurotoxicity. It is well known that mitochondria, which has been 
defined as organelles in tissue culture since 1914 [74] are normally involved in aging 
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process [75–77], since mitochondrial function declines as the age advances, result-
ing in decrease of ATP production and increase of free oxygen radicals formation, 
given that ATP synthase is located in the inner mitochondrial membrane, playing a 
key role in the energy homeostasis of the cell.
In addition, morphological alterations of mitochondria, resulting in deficiency 
of mitochondrial electron transport proteins, with considerable consequences upon 
the energy supply of nerve cells have been described in Alzheimer’s disease and 
other degenerative conditions of the brain [12, 21, 78, 79], which are also associated 
with oxidative stress [80].
It is also particularly noticeable that morphological abnormalities of mito-
chondria are seen in neurons lacking neurofibrillary tangles [12] suggesting that 
mitochondrial degeneration might be among the earliest signs of Alzheimer’s 
morphological alterations.
The fact that maternal influence seems to be a risk factor for Alzheimer’s disease 
morbidity, according to epidemiologic studies [81, 82], and to combined neuropsy-
chological and neuroimaging investigations [83] plead in favor of the substantial 
role that mitochondria may also play in the pathogenetic cascade of Alzheimer’s 
disease.
In this perspective article, we attempted to describe the ultrastructural altera-
tions of mitochondria in various neocortical and subcortical areas of the brain of 
patients who suffered from Alzheimer’s disease at the early stages.
2. Material and methods
2.1 Material
This electron microscope study is based on examination of 25 brains obtained at 
autopsy 2–7 hours after death at a room temperature of 40°C. All of the brains were 
derived from patients aged 55–80 years, who have had a history of dementia, which 
was definitely diagnosed 1 or 3 years prior to the end of their life.
The patients fulfilled on repeated clinical examinations and assessments all the 
psychological, psychiatric and neurological criteria of AD [84–86]. The patients 
have had 18 years of education, and had a fluency in their native language, two of 
them being also bilingual with equal fluency in both of the languages. The usual 
diagnostic assessment was based on the medical history, the physical examination, 
including cardiological investigation, neurological examination, psychiatric evalua-
tion and detailed neuropsychological testing.
The cognition of the patients was evaluated by battery of neuropsychological 
testing [87], including mini mental state examination (MMSE) [88, 89], dementia 
rating scale (DRS) [90, 91], ADAS-COX test [92, 93] and the brief memory execu-
tive test (BMET) [94].
All the patients underwent an EEG examination and a carotid examination by 
duplex Doppler. Neuroimaging was performed including computerized tomography 
(CT), magnetic resonance imaging (MRI) of the brain and a single-photon emission 
computed tomography (SPECT) [95]. All the methods of clinical and laboratory 
investigations were evocative for Alzheimer’s disease. The patients passed away due 
to heart arrest.
In addition, we dissected and examined in electron microscopy 25 brains, which 
were unremarkable from the neuropathological point of view, derived from appar-
ently healthy individuals of the same age range with the AD patients, using them as 
normal controls.
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2.2 Methods
2.2.1 Electron microscopy
Multiple samples of a small size (2 × 2 × 2 mm) were excised from the hippo-
campus, the prefrontal area of the cortex, the superior parietal lobe, the occipital 
pole, the visual cortex, the Hessl gyri of the temporal neocortex, the vermis of the 
cerebellum and the cerebellar hemispheres, the hypothalamus, the mammillary 
bodies and the medial geniculate bodies. The samples were selected bilaterally and 
immersed directly in Sotelo’s fixing solution [96], composed of 1% paraformalde-
hyde, 2.5% glutaraldehyde in cacodylate buffer 0.1 M, adjusted at pH 7.35.
Then all the specimens were post fixed in 1% osmium tetroxide for 30 min at 
a room temperature of 18°C and dehydrated in graded alcohol solutions and in 
propylene oxide twice. After dehydration, the specimens were embedded in araldite 
mixture and cut in ultrathin sections by a Reichert ultratome.
The sections were placed on the grids where they were contrasted with uranyl 
acetate and lead citrate, and studied in a Zeiss electron microscope of the type 9aS.
The study electron microscopy examination was particularly focused on the 
morphology of the organelles, mainly on the mitochondria of neurons and astro-
cytes. In addition, the Golgi complex, the endoplasmic reticulum, the endosomes, 
the dendritic profiles, the spines, the axons, the axonic collaterals and the synaptic 
components were studies in all of the sections.
The morphometric estimation was carried out on micrographs of a standard 
magnification of 56,000×. The analysis of each macrograph was performed with 
an image analyzer. The surface area of mitochondria as well as the volume and the 
circularity ratio (CR) were calculated on a total of 8000 mitochondria.
The statistical analysis of the data was evaluated by Student t tests.
3. Results
The ultrastructural study of the mitochondria revealed an impressive polymor-
phism at any area of the brain. The mitochondria demonstrated a wide variation of 
size and shape in the soma, the axons, the dendrites and the synaptic terminals in 
the majority of the neurons (Figure 1). The majority of the mitochondria demon-
strated fragmentation of the cristae and obvious disarrangement of their interior 
Figure 1. 
Large round mitochondrion in a dendritic profile in the molecular layer of the cerebellum in a case of 
AD. Electron micrograph Mag. 248,000×.
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structure (Figures 1 and 2). The mitochondria in the presynaptic terminals were 
either small and round with few cristae (Figure 3) or very large showing disruption 
of the cristae (Figure 4).
It should be underlined that in areas of the brain with minimal Alzheimer’s 
pathology, such as the cerebellum, the visual, the acoustic cortex, the mammil-
lary bodies and the hypothalamus, mitochondria demonstrated obvious mor-
phological alterations. Very large mitochondria were observed in the soma and 
the dendritic profiles of Purkinje cells (Figure 5), in the granule cells (Figure 6) 
as well as in the climbing fibers, the mossy fibers and the synaptic terminals of 
parallel fibers (Figure 7). Large number of small mitochondria with disruption 
of cristae was observed in the visual cortex (Figure 8) and the acoustic cortex 
(Figure 9).
Mitochondrial alterations were also observed in many synaptic profiles in the supra-
chiasmatic and the paraventricular hypothalamic nuclei of AD brains (Figure 10).
The morphometric estimation of the mitochondria in the soma, the dendrites 
and the dendritic spines of a considerable number of neurons of the suprachi-
asmatic nucleus in AD brains revealed that they have an average diameter of 
440 ± 250 nm and a mean axial ratio of 1.7 ± 0.2 [97].
The polymorphism of the mitochondria was the most frequent finding at 
any studied area of the cortex of the brain hemispheres, the cerebellum and the 
subcortical structures. Small round mitochondria intermixed with very large 
ones with disarrangement of the cristae and accumulation of fibrillary elements 
(Figure 11) or dense osmiophilic material (Figure 12). The mitochondria in the 
dendritic profiles and the synaptic terminals at the prefrontal cortex were large 
occupying the majority of the volume of the synaptic component (Figure 1). Large 
mitochondria were also observed in axonic collaterals among the myelinated fibers 
at the prefrontal and the parietal cortices (Figure 13). Small mitochondria were 
frequently observed in association with Golgi complex alterations in the soma of 
neurons and astrocytes (Figure 14).
A substantial number of astrocytes demonstrated small or very large mito-
chondria with disruption of the cristae in association with dilated cisternae of the 
smooth endoplasmic reticulum (Figure 15). Small mitochondria were also observed 
Figure 2. 
Large mitochondrion in a postsynaptic terminal in the molecular layer of the cerebellum in a case of AD. The 
disruption of the mitochondrial cristae is obvious. Electron micrograph Mag. 248,000×.
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Figure 3. 
Small round mitochondria in Purkinje cell dendritic spines (postsynaptic components) in the molecular layer 
of the cerebellum in a case of AD. Electron micrograph Mag. 248,000×.
Figure 5. 
Very elongated and large mitochondria in dendritic profiles (d) and dendritic spines (ds) in the molecular 
layer of the vermis of the cerebellum in a case of AD. The presynaptic terminals of the parallel fibers (pf) 
contain small round dense mitochondria. Electron micrograph Mag. 124,000×.
Figure 4. 
Very large mitochondria in dendritic profiles (d) and dendritic spines (ds) in the molecular layer of the 
cerebellum in a case of AD. The disruption of the mitochondrial cristae and the disarrangement of the interior 
structure are obvious. Electron micrograph Mag. 56,000×.
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in oligodendrocytes in the subcortical white mater in association with dilated 
cisternae of the smooth endoplasmic reticulum and alterations of the Golgi complex 
(Figure 16).
The dendritic spines of the cortical neurons were dramatically reduced in num-
ber and size and most of the presynaptic terminals included small round and dense 
mitochondria and were also characterized by the dramatic poverty of the synaptic 
vesicles (Figure 17), a finding advocating in favor of a previous concept that the 
Figure 6. 
Large abnormal mitochondria (m) in the perikaryon of a granule cell (GC) of the vermis of the cerebellum in 
a case of AD. Electron micrograph Mag. 124,000×.
Figure 7. 
Small dense mitochondria in a presynaptic terminal (pst) of a parallel fiber (pf) in contact with a large 
dendritic branch of Purkinje cell (PCd) in the molecular layer of the left cerebellar hemisphere in a case of 
AD. Electron micrograph Mag. 124,000×.
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Figure 9. 
Small dense mitochondria in postsynaptic terminal (ps) in the acoustic cortex in a case of AD. Electron 
micrograph Mag. 124,000×.
Figure 8. 
Mitochondria with obvious disruption of the cristae in presynaptic terminal (prs) in the visual cortex in a case 
of AD. Electron micrograph Mag. 124,000×.
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Figure 10. 
Small abnormal mitochondria with disruption of the cristae and disintegration of the interior structure in the 
suprachiasmatic nucleus of the hypothalamus in a case of AD. Electron micrograph Mag. 124,000×.
Figure 11. 
Very large mitochondria (m) intermixed with small ones (m) in a dendritic profile of Purkinje cell (PCd) in 
the vermis of the cerebellum in a case of AD. Electron micrograph Mag. 124,000×.
Redirecting Alzheimer Strategy - Tracing Memory Loss to Self Pathology
10
morphological alterations of the synapses and dendritic spines coincide, as a rule, 
with marked mitochondrial alterations [22].
In morphometric estimation, the mitochondria in normal control aged brains 
appeared to have an average diameter of 250–650 nm and a mean axial ratio of 
1.9 ± 0.2. The round or global mitochondria in normal controls appeared to have a 
mean mitochondrial radius of 350 nm. In Alzheimer’s disease, ellipsoid mitochon-
dria of Purkinje cells appeared to have an average diameter of 250–510 nm and a 
mean axial ratio of 1.7 ± 0.2. Round mitochondria were characterized by a mean 
radius of 280 nm.
Figure 13. 
Large mitochondrion in an axonic collateral among myelinated fibers in the prefrontal area of the cortex in a 
case of AD. Electron micrograph Mag. 124,000×.
Figure 12. 
Very small dense mitochondria in an axonic profile (ax) in the acoustic cortex in a case of AD. Electron 
micrograph Mag. 124,000×.
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Figure 14. 
Small mitochondrion (m) near dilated cisternae of Golgi apparatus (GA) and multivesicular body (mvb) 
in the soma of an astrocyte in the prefrontal area of the cortex of a case of AD. Electron micrograph Mag. 
54,000×.
Figure 15. 
Small mitochondria (m) among dilated cisternae of smooth endoplasmic reticulum (er) in the soma of an 
astrocyte in the parietal cortex of a case of AD. Electron micrograph Mag. 54,000×.
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4. Discussion
Mitochondria play an essential role in energy supply of the cells, given that they 
provide most of the energy by oxidative phosphorylation of glucose, been basely 
key organelles for energy production involved in many metabolic pathways of the 
cell [98]. Mitochondrial dysfunction, associated with aging may be also a crucial 
factor in neurodegenerative disorders including Alzheimer’s disease.
Decrease in energy metabolism and altered cytochrome C oxidase (CytOX) 
activity are among the earliest detectable defects in AD [99], affecting presumably 
neuronal plasticity and synaptogenesis. It is important to underline that reduced 
respiratory activity has also been reported in platelets of patients who suffered from 
AD [100], in the early stages of the disease. In addition, postmortem cytochrome-
C oxidase activity is lower than normal in the cerebral cortex and in the platelets 
of AD patients [101] and mutations in cytochrome-C oxidase genes have been 
reported in late-onset AD [102].
Mitochondria and mtDNA are very sensitive to oxidative damage, such as 
protein oxidation and lipid peroxidation and inversely mitochondrial alterations 
may induce or enhance the existing oxidative stress, a fact pleading for an intimate 
Figure 17. 
Small mitochondria (m) in presynaptic profiles which show a dramatic poverty of synaptic vesicles (v) in the 
molecular layer of the cerebellum of AD. Electron micrograph Mag. 124,000×.
Figure 16. 
Small mitochondria (m) among dilated cisternae of smooth endoplasmic reticulum (er) and fragmented 
cisternae of Golgi apparatus in the soma of an oligodendrocyte in the subcortical white matter of the parietal 
lobe of a case of AD. Electron micrograph Mag. 54,000×.
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and early association between oxidative stress and mitochondrial abnormalities 
[103, 104].
In addition, the combined effect of high calcium ions with oxidative stress may 
induce serious impairment of the mitochondrial function, leading to release of 
cytochrome C and triggering the initiation of the intrinsic pathway for apoptosis in 
many systems [105–107].
Oxidative stress can also enhance the production and the aggregation of 
Aβ [108] as well as the hyperphosphorylation of tau protein, which contribute 
extensively in the pathogenetic mechanism of AD [109]. The overproduction of 
Aβ peptide in AD induces fission and fragmentation of mitochondria, a fact that 
further increases oxidative stress and causes a considerable decline of energy 
production, which is associated with the increased expression of dynamin-related 
protein 1 (Drp1) [110]. The Aβ peptide enhances the activity of Drp1 protein in 
neurons, which subsequently induces morphological alteration of the mitochondria 
and increases the mitochondrial dysfunction in AD.
Mitochondrial alterations are closely connected with the over expression of the 
amyloid precursor protein (APP) and the amyloid-β peptide [58]. The Aβ peptides are 
generated either extracellularly or within the cisternae of the endoplasmic reticulum 
(ER) and the mitochondria. APP is folded and modified in the ER and transported 
through the Golgi complex to the plasma membrane. Transmembrane arrest of APP 
causes considerable impairment of mitochondrial function in neurons [111].
A substantial amount of amyloid-β peptide is generated in mitochondria-associ-
ated ER membranes (ER-MAMs or MAMs), which is a dynamic sub-compartment 
of the ER, which is connected with mitochondria [112]. In Alzheimer’s disease, 
intraneuronal amyloid precursor protein and amyloid-β are mostly localized to mito-
chondria [112], where amyloid-β peptide may induce mitochondrial dysfunctions by 
interaction with cyclophilin D, which is a subunit of the mitochondrial permeability 
transition pore [113]. Amyloid-β peptide may also interact with Aβ binding alcohol 
dehydrogenase (ABAD) on the mitochondrial membranes and induce further 
mitochondrial dysfunction [114]. Moreover, alterations in the lipid composition of 
cellular membranes may influence proteolytic processing of AβPP and increase the 
release of Alzheimer’s amyloid beta-peptide from membranes [115].
In addition, Aβ peptide inhibits protein influx in the mitochondria, resulting in 
mutation of mitochondrial DNA (mtDNA), aggravating therefore mitochondrial 
dysfunction and disintegration eventually [116]. Experimental studies, on the other 
hand, revealed that the soluble form of Aβ peptide causes a reduced mitochondrial 
membrane potential (MMP) and energy production [117].
Mitochondrial dysfunction on the other hand may play an important role for 
enhancing the neurotoxicity of the Aβ peptide in AD, aggravating furthermore the 
oxidative stress. Oxidative stress is reasonably associated with amyloid β peptide 
accumulation in the neocortex [118], a fact which plays a crucial role in the patho-
genesis of Alzheimer’s disease, inducing alterations to the cytoplasm of sensitive cells 
[119] by increasing reactive oxygen species (ROS) production [120]. This condition 
may cause further mitochondrial dysfunction, since the lack of histones in mito-
chondrial DNA makes them particularly vulnerable to oxidative stress [121, 122].
It is important that morphological alterations of the mitochondria in AD are 
observed in areas of the brain with minimal Alzheimer’s pathology, such as in the 
cerebellum, the hypothalamus and the mammillary bodies [123] suggesting that they 
are independent of the accumulation of neurofibrillary tangles and neuritic plaques.
It is well known that shape and the size of the mitochondria are highly variable 
[124], since they undergo continual fission and fusion, which are necessary for cell 
survival and harmonious adaptation to changing conditions [125] and are related, 
at the same time, with the processes of biogenesis [126] and the mitophagy [127].
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In addition, mitochondrial morphology is sometimes controlled by the cyto-
skeleton, namely the neurofilaments and the microtubules [128]. The change of 
the shape of the mitochondria occurs mostly during their course through axons, 
dendrites and synaptic terminals via anterograde transport [129].
Many proteins are also important for the mitochondrial morphological integrity 
and for binding to the cytoskeletal components [130]. Porin is a protein in the outer 
membrane of the mitochondria that forms voltage-dependent anionic channels, 
between the mitochondrial inter membrane space and the cytosol [131]. Porin 
may play crucial role in binding to cytoskeleton [132], because porin-rich domains 
mostly contain binding sites for MAP2. In addition, recent evidence suggest that 
amyloid β increases the contact points between endoplasmic reticulum and mito-
chondria, a phenomenon that occurs in cellular stress, which usually increases 
ER-mitochondrial coupling [133].
Normally, approximately one-third of the mitochondria are in motion along 
with microtubules and actin filaments [128, 134], transported to regions where 
energy requirement is particularly high. The number of the mitochondria is 
adjusted, according to the requirement of energy by the cell. It is reasonable that the 
dysfunctional mitochondria may undergo mitophagy [135], a fact which is associ-
ated with neurodegeneration [136] and many devastating conditions of the brain.
Morphometric studies of the mitochondria in non-nerve cells in AD revealed a 
significant reduction in mitochondrial density in endothelial cells [137] as well as 
in fibroblasts and other cells obtained from patients with AD [138]. Mitochondria 
from fibroblasts grown in tissue culture from skin samples taken during autopsy of 
patients of AD, took significantly less calcium than did mitochondria of fibroblasts 
from age matched normal controls, suggesting that Alzheimer’s fibroblast mito-
chondria have impaired calcium transport processes and showed increased sensitiv-
ity to oxygenic free radicals [139].
The most dramatic morphological alterations of the mitochondria are seen in 
dendritic profiles and the synaptic terminals. The defective mitochondria in AD 
neurons may not supply adequate levels of adenosine triphosphate (ATP), which is 
very important factor at the synaptic level for normal neural communication. The 
low levels of cellular ATP at nerve terminals may lead to the loss of synapses and 
considerable decline of synaptic function, causing serious cognitive impairment 
and profound dementia ultimately.
Mitochondrial alterations in AD are observed also in astrocytes, although mito-
chondrial dynamics of astrocytes are not yet extensively studied. Astrocytes partici-
pate in the degradation of neuronal mitochondria via the process of transmitophagy 
[140] that occurs following internalization of axonal mitochondria by astrocytic 
processes, which normally contain very small mitochondria [141]. Astrocytic 
alterations have been described in cases of familial Alzheimer’s disease [142] as well 
as in advanced cased of sporadic type of Alzheimer’s disease [143], demonstrating 
evidence of the toxicity of the Aβ peptide [144]. The mitochondrial alterations of 
the astrocytes in early case of Alzheimer’s disease enhance the noxious role of the 
Aβ peptide on the function and the integrity of the astrocytes [145] with serious 
implications on neuroprotection [146] due to the increased excitotoxicity, which 
would be a reasonable consequence of the disruption of glutamate/GABA-glutamine 
cycle [147].
In all of the cases, it was noticed that the morphological alterations of mitochon-
dria in neurons and astrocytes are frequently associated with the fragmentation 
of Golgi apparatus and the decrease of the vesicles in cis- and trans-Golgi network 
[19, 56]. The morphological alterations of the mitochondria and the fragmentation 
of Golgi complex coincide with the dendritic and synaptic pathology in early cases 
of Alzheimer’s disease [22, 148].
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Understanding the important role the mitochondrial factor plays in the etio-
pathogenetic cascade of Alzheimer’s disease [13], new therapeutic strategies aim 
at protecting the mitochondria [149] and preventing oxidative stress, calcium 
imbalance and eventual apoptosis might be beneficial in the treatment of early 
cases of AD.
5. Conclusions
The study in electron microscopy of various areas of the cerebral cortex, includ-
ing the prefrontal area, the superior parietal lobe, the occipital pole, the visual cor-
tex and the Hessl gyri of the temporal neocortex, and various areas of the cerebellar 
cortex, the hypothalamus, the mammillary bodies and the medial geniculate body 
in early cases of Alzheimer’s disease, revealed serious morphological alterations 
of the mitochondria in the perikaryon, the dendritic branches the axons and the 
synapses.
The most dramatic alteration of the mitochondrial morphology was observed 
in the dendritic profiles, the dendritic spines and the synapses, associated with 
poverty of synaptic vesicles and accumulation of multi vesicular bodies.
The morphological alterations of the mitochondria were not dependent on the 
typical Alzheimer’s pathology, since they were seen in areas with minimal β amyloid 
aggregations and no neurofibrillary tangles, such as the cerebellum, the hypothala-
mus and the visual cortex, suggesting that the mitochondrial alterations are not the 
direct consequence of amyloid toxicity.
Mitochondrial alterations were also seen in astrocytes and oligodendrocytes 
frequently in association with dilatation of the cisternae of the smooth endoplasmic 
reticulum and Golgi complex.
The mitochondria alterations induce a substantial decline of energy supply to 
neuronal processes, affecting the protein trafficking, the membrane dynamics as 
well as the synaptic activity, resulting in gradual synaptic and dendritic degenera-
tion and in neuronal apoptosis eventually.
Mitochondria are strategic points in the pathogenetic field of Alzheimer’s dis-
ease. New therapeutic strategies aiming at protecting the mitochondria, increasing 
the energy supply and preventing oxidative stress and calcium imbalance, might be 
beneficial in the treatment of early cases of AD.
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